- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
International Journal of Alzheimer's Disease
Volume 2012 (2012), Article ID 673584, 7 pages
Bupropion and Citalopram in the APP23 Mouse Model of Alzheimer's Disease: A Study in a Dry-Land Maze
1Division of Mental Health & Old Age Psychiatry, Psychiatry II, Ulm University, 89312 Günzburg, Germany
2Department of Geriatrics & Old Age Psychiatry, Psychiatry II, Ulm University, Ludwig-Heilmeyer-Straße 2, 89312 Günzburg, Germany
Received 29 March 2012; Accepted 3 September 2012
Academic Editor: Francesco Panza
Copyright © 2012 Katharina L. Neumeister and Matthias W. Riepe. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. C. Youn, D. Y. Lee, J. H. Jhoo, K. W. Kim, I. H. Choo, and J. I. Woo, “Prevalence of neuropsychiatric syndromes in Alzheimer's disease (AD),” Archives of Gerontology and Geriatrics, vol. 52, no. 3, pp. 258–263, 2011.
- T. C. Kuo, Y. Zhao, S. Weir, M. S. Kramer, and A. S. Ash, “Implications of comorbidity on costs for patients with alzheimer disease,” Medical Care, vol. 46, no. 8, pp. 839–846, 2008.
- M. Benoit, P. Staccini, P. Brocker et al., “Behavioral and psychological symptoms in Alzheimer's disease: results from REAL.FR study,” Revue de Medecine Interne, vol. 24, supplement 3, pp. 319s–324s, 2003.
- C. G. Lyketsos, O. Lopez, B. Jones, A. L. Fitzpatrick, J. Breitner, and S. Dekosky, “Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study,” Journal of the American Medical Association, vol. 288, no. 12, pp. 1475–1483, 2002.
- M. Benoit, P. H. Robert, P. Staccini et al., “One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer's disease. The REAL.FR study,” Journal of Nutrition, Health and Aging, vol. 9, no. 2, pp. 95–99, 2005.
- L. Lechowski, M. Benoit, P. Chassagne et al., “Persistent apathy in Alzheimer's disease as an independent factor of rapid functional decline: the REAL longitudinal cohort study,” International Journal of Geriatric Psychiatry, vol. 24, no. 4, pp. 341–346, 2009.
- S. E. Starkstein, R. Jorge, R. Mizrahi, and R. G. Robinson, “A prospective longitudinal study of apathy in Alzheimer's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 1, pp. 8–11, 2006.
- B. Winblad, J. Hardy, L. Backman, and L. G. Nilsson, “Memory function and brain biochemistry in normal aging and in senile dementia,” Annals of the New York Academy of Sciences, vol. 444, pp. 255–268, 1985.
- E. Mohr, T. Mendis, I. N. Rusk, and J. D. Grimes, “Neurotransmitter replacement therapy in Alzheimer's disease,” Journal of Psychiatry and Neuroscience, vol. 19, no. 1, pp. 17–23, 1994.
- D. M. Mann and P. O. Yates, “Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders,” Human Neurobiology, vol. 5, no. 3, pp. 147–158, 1986.
- C. G. Gottfries, R. Adolfsson, and S. M. Aquilonius, “Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT),” Neurobiology of Aging, vol. 4, no. 4, pp. 261–271, 1983.
- R. Ganguly and D. Guha, “Alteration of brain monoamines & EEG wave pattern in rat model of Alzheimer's disease & protection by Moringa oleifera,” Indian Journal of Medical Research, vol. 128, no. 6, pp. 744–751, 2008.
- M. T. Heneka, M. Ramanathan, A. H. Jacobs et al., “Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice,” Journal of Neuroscience, vol. 26, no. 5, pp. 1343–1354, 2006.
- E. Richelson and M. Pfenning, “Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake,” European Journal of Pharmacology, vol. 104, no. 3-4, pp. 277–286, 1984.
- I. Herrera-Guzmán, E. Gudayol-Ferré, J. Lira-Mandujano et al., “Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder,” Psychiatry Research, vol. 160, no. 1, pp. 72–82, 2008.
- Y. Kitamura, T. Yagi, K. Kitagawa et al., “Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 382, no. 2, pp. 151–158, 2010.
- N. Sidhpura, P. Redfern, H. Rowley, D. Heal, and S. Wonnacott, “Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo,” Biochemical Pharmacology, vol. 74, no. 8, pp. 1292–1298, 2007.
- R. W. Fuller, “Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research,” Progress in Drug Research, vol. 45, pp. 167–204, 1995.
- S. Hjorth, D. Westlin, and H. J. Bengtsson, “WAY100635-induced augmentation of the 5-HT-elevating action of citalopram: relative importance of the dose of the 5-HT(1A) (Auto)receptor blocker versus that of the 5-HT reuptake inhibitor,” Neuropharmacology, vol. 36, no. 4-5, pp. 461–465, 1997.
- J. Hyttel, “Citalopram—pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 6, no. 3, pp. 277–295, 1982.
- N. Egashira, Y. Matsumoto, K. Mishima et al., “Low dose citalopram reverses memory impairment and electroconvulsive shock-induced immobilization,” Pharmacology Biochemistry and Behavior, vol. 83, no. 1, pp. 161–167, 2006.
- A. V. Kulikov, M. A. Tikhonova, D. V. Osipova, V. A. Kulikov, and N. K. Popova, “Association between tryptophan hydroxylase-2 genotype and the antidepressant effect of citalopram and paroxetine on immobility time in the forced swim test in mice,” Pharmacology Biochemistry and Behavior, vol. 99, no. 4, pp. 683–687, 2011.
- R. Hellweg, P. Lohmann, R. Huber, A. Kühl, and M. W. Riepe, “Spatial navigation in complex and radial mazes in APP23 animals and neurotrophin signaling as a biological marker of early impairment,” Learning and Memory, vol. 13, no. 1, pp. 63–71, 2006.
- K. S. Lashley and S. I. Franz, “The effects of cerebral destruction upon habit-formation and retention in the albino rat,” Psychobiology, vol. 1, no. 2, pp. 71–139, 1912.
- R. G. M. Morris, “Spatial localization does not require the presence of local cues,” Learning and Motivation, vol. 12, no. 2, pp. 239–260, 1981.
- F. E. Harrison, A. H. Hosseini, and M. P. McDonald, “Endogenous anxiety and stress responses in water maze and Barnes maze spatial memory tasks,” Behavioural Brain Research, vol. 198, no. 1, pp. 247–251, 2009.
- C. Lange-Asschenfeldt, P. Lohmann, and M. W. Riepe, “Hippocampal synaptic depression following spatial learning in a complex maze,” Experimental Neurology, vol. 203, no. 2, pp. 481–485, 2007.
- C. Lange-Asschenfeldt, P. Lohmann, and M. W. Riepe, “Spatial performance in a complex maze is associated with persistent long-term potentiation enhancement in mouse hippocampal slices at early training stages,” Neuroscience, vol. 147, no. 2, pp. 318–324, 2007.
- D. Cao, H. Lu, T. L. Lewis, and N. Li, “Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease,” Journal of Biological Chemistry, vol. 282, no. 50, pp. 36275–36282, 2007.
- D. Van Dam, D. Abramowski, M. Staufenbiel, and P. P. De Deyn, “Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model,” Psychopharmacology, vol. 180, no. 1, pp. 177–190, 2005.
- P. L. Pugh, J. C. Richardson, S. T. Bate, N. Upton, and D. Sunter, “Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease,” Behavioural Brain Research, vol. 178, no. 1, pp. 18–28, 2007.
- N. Majlessi and N. Naghdi, “Impaired spatial learning in the Morris water maze induced by serotonin reuptake inhibitors in rats,” Behavioural Pharmacology, vol. 13, no. 3, pp. 237–242, 2002.
- B. R. Brookshire and S. R. Jones, “Direct and indirect 5-HT receptor agonists produce gender-specific effects on locomotor and vertical activities in C57 BL/6J mice,” Pharmacology Biochemistry and Behavior, vol. 94, no. 1, pp. 194–203, 2009.
- M. Brocco, A. Dekeyne, S. Veiga, S. Girardon, and M. J. Millan, “Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake: a pharmacological characterization of diverse classes of antidepressant agents,” Pharmacology Biochemistry and Behavior, vol. 71, no. 4, pp. 667–680, 2002.
- A. L. Nyth and C. G. Gottfries, “The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study,” British Journal of Psychiatry, vol. 157, pp. 894–901, 1990.
- J. Caballero, M. Hitchcock, D. Beversdorf, D. Scharre, and M. Nahata, “Long-term effects of antidepressants on cognition in patients with Alzheimer's disease,” Journal of Clinical Pharmacy and Therapeutics, vol. 31, no. 6, pp. 593–598, 2006.
- A. S. Rauhut, M. Hawrylak, and S. K. Mardekian, “Bupropion differentially alters the aversive, locomotor and rewarding properties of nicotine in CD-1 mice,” Pharmacology Biochemistry and Behavior, vol. 90, no. 4, pp. 598–607, 2008.